NCT02805218已完成4 期
The Multi-center,Open-label,Single Arm Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.0 个研究点目标入组 410 人开始时间: 2013年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 410
- 主要终点
- The occurrence rate of adverse event
研究概览
简要总结
The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lymphoma receiving chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with age ≥ 18 years
- •diagnosis of lymphoma(Hodgkin's lymphoma and non-Hodgkin's lymphoma) patients
- •Karnofsky Performance Status Z70
- •life expectancy of at least 8 months
- •normal white blood cell count and platelet count
- •Written informed consent are acquired
排除标准
- •uncontrolled infection
- •pregnancy
- •Have accepted any other anti-tumor drug within 4 weeks before anticipated the study
- •Other situations that investigators consider as contra-indication for this study
研究组 & 干预措施
PEG-rhG-CSF
Experimental
patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy
干预措施: PEG-rhG-CSF (Drug)
结局指标
主要结局
The occurrence rate of adverse event
时间窗: up to 30 days after the patient study completion
The severity of adverse event
时间窗: up to 30 days after the patient study completion
次要结局
- the occurrence rate of grade III/ IV neutropenia during chemotherapy cycles(through the study completion,an average of 5 months)
研究者
相似试验
已完成
4 期
PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving ChemotherapyMalignant Solid TumorsNCT02805166CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.420
已完成
4 期
PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent NeutropeniaBreast CancerNCT02805205CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.484
已完成
4 期
PEG-rhG-CSF in Patients With Breast Cancer Receiving ChemotherapyBreast CancerNCT02805153CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.215
已完成
4 期
The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive ChemotherapyBreastcancerNCT02944604Peking University240
Unknown
不适用
PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell TransplantationLymphomaNCT05156554Sun Yat-sen University80